These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34194745)

  • 1. Prognostic value of programmed cell death ligand-1 expression in the tumor-infiltrating immune cells of patients with lung cancer: A meta-analysis.
    Berele BA; Yang G; Wu T
    Mol Clin Oncol; 2021 Aug; 15(2):167. PubMed ID: 34194745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.
    Zhao T; Li C; Wu Y; Li B; Zhang B
    PLoS One; 2017; 12(4):e0176822. PubMed ID: 28453554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of programmed cell death ligand 1 (PD-L1) involves in the clinicopathologic characteristics and prognostic implications of testicular germ cell tumor (TGCT): a systematic review and meta-analysis.
    Li P; Zhong Y; Zhang M; Zheng Y; Peng W
    Transl Cancer Res; 2024 Aug; 13(8):3944-3959. PubMed ID: 39262473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
    Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
    Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
    Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
    Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
    Li J; Wang P; Xu Y
    PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
    Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
    Front Oncol; 2019; 9():897. PubMed ID: 31620360
    [No Abstract]   [Full Text] [Related]  

  • 11. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.
    Huang ZL; Liu S; Wang GN; Zheng SH; Ding SR; Tao YL; Chen C; Liu SR; Yang X; Chang H; Wang XH; Xia YF
    Cancer Cell Int; 2019; 19():141. PubMed ID: 31139018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
    Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
    J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis.
    Wang YM; Cai W; Xue QM; Zhang JY; Zhou L; Xiong SY; Deng H
    Front Immunol; 2023; 14():1234894. PubMed ID: 37654479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
    Wen Y; Chen Y; Duan X; Zhu W; Cai C; Deng T; Zeng G
    Clin Exp Med; 2019 Nov; 19(4):407-416. PubMed ID: 31407099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
    Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
    Front Immunol; 2018; 9():2077. PubMed ID: 30254644
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis.
    Guo W; Wang P; Li N; Shao F; Zhang H; Yang Z; Li R; Gao Y; He J
    Oncotarget; 2018 Mar; 9(17):13920-13933. PubMed ID: 29568405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
    Lotfinejad P; Asghari Jafarabadi M; Abdoli Shadbad M; Kazemi T; Pashazadeh F; Sandoghchian Shotorbani S; Jadidi Niaragh F; Baghbanzadeh A; Vahed N; Silvestris N; Baradaran B
    Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32957579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients.
    Gu X; Gao XS; Xiong W; Guo W; Han L; Bai Y; Peng C; Cui M; Xie M
    Onco Targets Ther; 2016; 9():4805-13. PubMed ID: 27536144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X
    Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.